

Wright Medical Group N.V.
Supplemental Net Sales Information
(unaudited)

Three months ended June 25, 2017 net sales growth/(decline)

Product line	<u>U.S. as reported</u>	<u>Int'l constant currency</u>	<u>Int'l as reported</u>	<u>Global constant currency</u>	<u>Global as reported</u>
Lower extremities	4%	(5%)	(9%)	2%	1%
Upper extremities	15%	(1%)	(4%)	10%	9%
Biologics	8%	8%	5%	8%	8%
Sports med & other	(18%)	7%	2%	(2%)	(5%)
Total net sales	9%	(1%)	(4%)	6%	5%

Six months ended June 25, 2017 net sales growth/(decline)

Product line	<u>U.S. as reported</u>	<u>Int'l constant currency</u>	<u>Int'l as reported</u>	<u>Global constant currency</u>	<u>Global as reported</u>
Lower extremities	2%	(7%)	(11%)	0%	(1%)
Upper extremities	14%	4%	1%	11%	10%
Biologics	9%	15%	14%	10%	10%
Sports med & other	(10%)	4%	(2%)	(1%)	(5%)
Total net sales	8%	2%	(2%)	6%	5%

Wright Medical Group N.V.

Reconciliation of Adjusted Non-GAAP Earnings Per Share to Net Loss from Continuing Operations Per Share

(dollars in thousands, except per share data--unaudited)

	Three months ended		Six months ended	
	June 25, 2017	June 26, 2016	June 25, 2017	June 26, 2016
Net loss from continuing operations, as reported	\$ (20,960)	\$ (42,031)	\$ (57,667)	\$ (82,223)
Net loss from continuing operations per share, as reported	\$ (0.20)	\$ (0.41)	\$ (0.55)	\$ (0.80)
Reconciling items:				
Inventory step-up amortization	—	10,387	—	20,616
Non-cash interest expense on convertible notes ¹	11,249	8,240	22,248	15,296
Non-cash loss on extinguishment of debt	—	12,343	—	12,343
Derivatives mark-to-market adjustments ²	(4,329)	(16,632)	(3,964)	(23,273)
Transaction and transition costs	3,201	9,014	6,173	19,847
Management changes	—	1,348	—	1,348
CVR mark-to-market adjustments ²	(3,924)	1,401	2,236	6,725
Contingent consideration fair value adjustment ²	176	306	176	306
Legal settlement	—	1,800	—	1,800
Costs associated with 2021 Notes issuance	—	234	—	234
IRS settlement ³	—	(3,073)	—	(3,073)
Tax effect of reconciling items ⁴	(52)	(2,132)	(70)	(3,321)
Non-GAAP net loss from continuing operations, as adjusted	\$ (14,639)	\$ (18,795)	\$ (30,868)	\$ (33,375)
Add back amortization of intangible assets	6,999	7,484	14,396	13,941
Adjusted non-GAAP earnings	\$ (7,640)	\$ (11,311)	\$ (16,472)	\$ (19,434)
Weighted-average basic shares outstanding	104,377	102,785	104,020	102,745
Adjusted non-GAAP earnings per share	\$ (0.07)	\$ (0.11)	\$ (0.16)	\$ (0.19)

¹ Impacting interest expense, net

² Impacting other (income) expense, net

³ IRS Settlement includes \$0.8 million of interest income and \$2.3 million tax benefit.

⁴ Determined based upon the effective tax rate in the jurisdiction in which the expense was incurred.

Wright Medical Group N.V.
Reconciliation of Non-GAAP Adjusted EBITDA to Net Loss from Continuing Operations
(dollars in thousands--unaudited)

	Three months ended		Six months ended	
	June 25, 2017	June 26, 2016	June 25, 2017	June 26, 2016
Net loss from continuing operations	\$ (20,960)	\$ (42,031)	\$ (57,667)	\$ (82,223)
Interest expense, net	18,339	13,024	36,534	24,878
Provision (benefit) from income taxes	385	(3,300)	1,324	(4,588)
Depreciation	13,678	13,270	27,124	26,120
Amortization	6,999	7,484	14,396	13,941
Non-GAAP EBITDA	\$ 18,441	\$ (11,553)	\$ 21,711	\$ (21,872)
Reconciling items impacting EBITDA:				
Non-cash share-based compensation expense	4,732	3,056	8,686	6,373
Other (income) expense, net	(6,557)	(2,061)	1,418	(3,129)
Inventory step-up amortization	—	10,387	—	20,616
Transaction and transition costs	3,201	9,014	6,173	19,847
Management changes	—	1,348	—	1,348
Legal settlement	—	1,800	—	1,800
Costs associated with 2021 Notes issuance	—	234	—	234
Non-GAAP adjusted EBITDA	\$ 19,817	\$ 12,225	\$ 37,988	\$ 25,217
Net sales from continuing operations	179,693	170,716	356,884	340,007
Non-GAAP adjusted EBITDA margin	11.0%	7.2%	10.6%	7.4%

Wright Medical Group N.V.
Reconciliation of Non-GAAP Adjusted Gross Margins to Gross Margins from Continuing Operations
(dollars in thousands--unaudited)

	Three months ended		Six months ended	
	June 25, 2017	June 26, 2016	June 25, 2017	June 26, 2016
Gross profit from continuing operations, as reported	\$ 141,571	\$ 121,707	\$ 281,636	\$ 244,332
Gross margins from continuing operations, as reported	78.8 %	71.3 %	78.9 %	71.9 %
Reconciling items impacting gross profit:				
Inventory step-up amortization	—	10,387	—	20,616
Transaction and transition costs	—	1,954	685	2,078
Non-GAAP gross profit from continuing operations, as adjusted	\$ 141,571	\$ 134,048	\$ 282,321	\$ 267,026
Net sales from continuing operations	179,693	170,716	356,884	340,007
Non-GAAP adjusted gross margins from continuing operations	78.8%	78.5%	79.1%	78.5%

Wright Medical Group N.V.
Reconciliation of Other Non-GAAP Financial Measures to Other As Reported Results
(dollars in thousands--unaudited)

	Three months ended		Six months ended	
	June 25, 2017	June 26, 2016	June 25, 2017	June 26, 2016
Net sales	\$ 179,693	\$ 170,716	\$ 356,884	\$ 340,007
Selling, general and administrative expense, as reported	\$ 130,818	\$ 136,483	\$ 260,652	\$ 271,229
Selling, general and administrative expense as a percentages of net sales, as reported	72.8 %	79.9 %	73.0 %	79.8 %
Reconciling items impacting selling, general and administrative expense:				
Transaction and transition costs - selling, general and administrative	3,101	6,970	5,388	17,530
Management changes	—	1,348	—	1,348
Legal settlement	—	1,800	—	1,800
Costs associated with 2021 Notes issuance	—	234	—	234
Selling, general and administrative expense, as adjusted	\$ 127,717	\$ 126,131	\$ 255,264	\$ 250,317
Selling, general and administrative expense as a percentage of net sales, as adjusted	71.1%	73.9%	71.5%	73.6%
Research & development expense, as reported	\$ 12,547	\$ 12,108	\$ 24,979	\$ 24,224
Research & development expense as a percentages of net sales, as reported	7.0 %	7.1 %	7.0 %	7.1 %
Reconciling items impacting research & development expense:				
Transaction and transition costs - research & development	100	90	100	239
Research & development expense, as adjusted	\$ 12,447	\$ 12,018	\$ 24,879	\$ 23,985
Research & development expense as a percentage of net sales, as adjusted	6.9%	7.0%	7.0%	7.1%